

PharmaNet Bulletin

PLEASE INSERT IN YOUR PHARMACARE/PHARMA.NET: POLICIES AND PROCEDURES MANUAL

PharmaNet Descriptions of New Clinical Effect Codes

Drug-Drug Interaction Module™ (DDIM)

Effective February 24, 2005, First DataBank introduced the following changes to the Drug-Drug Interaction Module™ (DDIM):

- Refined description of drug interaction Severity Level 1, resulting in the reclassification of certain drug-drug interactions to Severity Level 2; and
- Four new clinical effect codes.

On PharmaNet, the new Clinical Effect Code descriptions must be shortened to 20 characters. They will appear as shown in the chart below.

Code	Description	PharmaNet Description	Details
CEE	Conflicting evidence exists in the medical literature.	Conflicting evidence	Indicates that some literature suggests that a combination contraindicated by the manufacturer can be used in some patients.
AVD	Avoid concurrent use when possible.	Avoid concurrent use	Indicates that the manufacturer labelling for an interaction states that "concurrent use should be avoided." These are the interactions that have been reclassified from Severity Level 1 to Severity Level 2 effective February 24, 2005.
CIS	Contraindicated in some patients.	Contraindic some pat	Identifies Severity Level 2 interactions that are contraindicated in some patients, such as the elderly or those with renal impairment. The populations for whom the drug combination is contraindicated are identified in the DDIM monograph.
LBC	Labelling content conflicts between countries or products.	Labeling conflicts	Identifies interactions for which labelling differs between: <ul style="list-style-type: none"> • products (e.g., labelling on one product says to "avoid" the drug combination while labelling on another product says the combination is "contraindicated"), or • countries (e.g., U.S. labelling says to "use caution" with the combination while Canadian labelling says the combination is "contraindicated").